Metrion Biosciences and Concept Life Sciences Announce Strategic Alliance
Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and Concept Life Sciences (Concept), the business formed in 2014 to break into the international integrated discovery & development and analytical markets, today announced a strategic alliance to provide pharmaceutical clients with fully integrated medicinal chemistry and biology research services for ion channel drug discovery.
The agreement brings together Metrion’s expertise in ion channel assay development, validation and compound screening with Concept’s strength in providing medicinal chemistry, analytical chemistry, in-vitro ADME assays and investigational toxicology services. Combined with Metrion’s recently announced alliance with Assay.Works, the partnership provides an ’end to end‘ service for pharmaceutical clients wishing to conduct new ion channel targeted drug discovery projects.
Ion channel dysfunction is increasingly recognised as a key factor in the pathogenesis of many chronic and difficult to treat diseases. The combined specialist team presents a unique opportunity in contract research, to collaborate with Metrion from an initial hit finding high throughput screen to nomination of a development candidate.
Metrion and Concept will jointly promote the new service, and it will also be made available to existing clients of both companies. Financial terms are not disclosed but the partners will share revenues and potential milestone success payments from the contract research projects. The partners are also prepared to offer risk sharing arrangements to clients.
Dr Andrew Southan, Head of Commercial Operations at Metrion Biosciences said: “We are delighted to be working closely with Concept and are impressed by their capabilities. Concept has an excellent track record in discovery and development science, and acquired its highly experienced medicinal chemistry team from Pfizer, UK. Through this strategic alliance, Metrion is able to intiate and manage high quality integrated drug discovery projects on behalf of pharmaceutical clients interested in addressing some of the exciting, recently identified, ion channel disease targets.”
Dr Paul Doyle, Group Chief Scientific Officer, Concept Life Sciences, commented: “Metrion’s high level of expertise in ion channel drug discovery is an ideal match for Concept. We have built an organisation that delivers one of the widest ranges of chemical and analytical services available in Europe, and we are now pleased to also be working alongside the scientists at Metrion.”
This article has been republished from materials provided by Metrion. Note: material may have been edited for length and content. For further information, please contact the cited source.
Researchers Uncover Muscle Growth Inhibitor Activation Mechanism Aiding ALS Treatment EffortsNews
Researchers at the University of Cincinnati (UC) College of Medicine are part of an international team that has identified how the inactive or latent form of GDF8, a signaling protein also known as myostatin responsible for limiting muscle, is activated.READ MORE
New Research Could Significantly Accelerate Drug DiscoveryNews
Scientists have developed a suite of computer programs that cull through data on structure and genomic sequencing to identify the features that distinguish one enzyme from similar enzymes. This research has the potential to significantly accelerate drug discovery, allowing scientists to develop more effective drugs, more quickly.READ MORE
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.